{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:27:59Z","timestamp":1791329279387,"version":"4.3.1"},"reference-count":73,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2024.0111","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T09:35:59Z","timestamp":1724837759000},"source":"Crossref","is-referenced-by-count":3,"title":["Hereditary hemorrhagic telangiectasia (Osler\u2019s disease): systemic, interdisciplinary, relatively common\u2014and often missed"],"prefix":"10.3238","author":[{"given":"Urban W.","family":"Geisthoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Mahnken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike W.","family":"Denzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Kemmling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Nimsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris A.","family":"Stuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"10.3238\/arztebl.m2024.0111_ref1","doi-asserted-by":"crossref","unstructured":"Droege F, Kuerten CHL, Kaiser C, et al.: Heredit\u00e4re h\u00e4morrhagische Teleangiektasie: Symptome und diagnostische Latenz. Laryngorhinootologie 2021; 100: 443–52.","DOI":"10.1055\/a-1408-5160"},{"key":"10.3238\/arztebl.m2024.0111_ref2","doi-asserted-by":"crossref","unstructured":"de Gussem EM, Kroon S, Hosman AE, et al.: Hereditary hemorrhagic telangiectasia (HHT) and survival: the importance of systematic screening and treatment in HHT centers of excellence. J Clin Med 2020; 9: 3581.","DOI":"10.3390\/jcm9113581"},{"key":"10.3238\/arztebl.m2024.0111_ref3","doi-asserted-by":"crossref","unstructured":"de Gussem EM, Edwards CP, Hosman AE, et al.: Life expextancy of parents with hereditary haemorrhagic telangiectasia. Orphanet J Rare Dis 2016; 11: 46.","DOI":"10.1186\/s13023-016-0427-x"},{"key":"10.3238\/arztebl.m2024.0111_ref4","unstructured":"Faughnan ME, Mager JJ, Hetts SW, et al.: Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. Ann Intern Med 2020; 173: 989–1001."},{"key":"10.3238\/arztebl.m2024.0111_ref5","unstructured":"Faughnan ME, Palda VA, Garcia-Tsao G, et al.: International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011; 48: 73–87."},{"key":"10.3238\/arztebl.m2024.0111_ref6","unstructured":"Goldbloom R, Battista RN: The periodic health examination: 1. Introduction. CMAJ 1986; 134: 721–3."},{"key":"10.3238\/arztebl.m2024.0111_ref7","doi-asserted-by":"crossref","unstructured":"Balshem H, Helfand M, Schunemann HJ, et al.: GRADE guidelines: 3. rating the quality of evidence. J Clin Epidemiol 2011; 64: 401–6.","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"10.3238\/arztebl.m2024.0111_ref8","doi-asserted-by":"crossref","unstructured":"Chitsuthipakorn W, Hoang MP, Kanjanawasee D, Seresirikachorn K, Snidvongs K: Treatments of epistaxis in hereditary hemorrhagic telangiectasia: systematic review and network meta-analysis. Curr Allergy Asthma Rep 2023; 23: 689–701.","DOI":"10.1007\/s11882-023-01116-8"},{"key":"10.3238\/arztebl.m2024.0111_ref9","doi-asserted-by":"crossref","unstructured":"Hsu YP, Hsu CW, Bai CH, Cheng SW, Chen C: Medical treatment for epistaxis in hereditary hemorrhagic telangiectasia: a meta-analysis. Otolaryngol Head Neck Surg 2019; 160: 22–35.","DOI":"10.1177\/0194599818797316"},{"key":"10.3238\/arztebl.m2024.0111_ref10","doi-asserted-by":"crossref","unstructured":"Shovlin CL, Guttmacher AE, Buscarini E, et al.: Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91: 66–7.","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P"},{"key":"10.3238\/arztebl.m2024.0111_ref11","unstructured":"McDonald J, Stevenson DA: Hereditary Hemorrhagic Telangiectasia. In: Adam MP, Mirzaa GM, Pagon RA, et al., (eds.): GeneReviews, Seattle (WA)1993."},{"key":"10.3238\/arztebl.m2024.0111_ref12","doi-asserted-by":"crossref","unstructured":"van Gent MW, Post MC, Luermans JG, et al.: Screening for pulmonary arteriovenous malformations using transthoracic contrast echocardiography: a prospective study. Eur Respir J 2009; 33: 85–91.","DOI":"10.1183\/09031936.00049008"},{"key":"10.3238\/arztebl.m2024.0111_ref13","doi-asserted-by":"crossref","unstructured":"van Gent MWF, Post MC, Snijder RJ, et al.: Grading of pulmonary right-to-left shunt with transthoracic contrast echocardiography: does it predict the indication for embolotherapy? Chest 2009; 135: 1288–92.","DOI":"10.1378\/chest.08-1266"},{"key":"10.3238\/arztebl.m2024.0111_ref14","doi-asserted-by":"crossref","unstructured":"Shovlin CL, Jackson JE, Bamford KB, et al.: Primary determinants of ischaemic stroke\/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia. Thorax 2008; 63: 259–66.","DOI":"10.1136\/thx.2007.087452"},{"key":"10.3238\/arztebl.m2024.0111_ref15","doi-asserted-by":"crossref","unstructured":"Geisthoff U: Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. Ann Intern Med 2021; 174: 1034–5.","DOI":"10.7326\/L21-0066"},{"key":"10.3238\/arztebl.m2024.0111_ref16","doi-asserted-by":"crossref","unstructured":"Eker OF, Boccardi E, Sure U, et al.: European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT). Orphanet J Rare Dis 2020; 15: 165.","DOI":"10.1186\/s13023-020-01386-9"},{"key":"10.3238\/arztebl.m2024.0111_ref17","doi-asserted-by":"crossref","unstructured":"Chavan A, Schumann-Binarsch S, Schmuck B, et al.: Emerging role of bevacizumab in management of patients with symptomatic hepatic involvement in hereditary hemorrhagic telangiectasia. Am J Hematol 2017; 92: E641–E4.","DOI":"10.1002\/ajh.24878"},{"key":"10.3238\/arztebl.m2024.0111_ref18","doi-asserted-by":"crossref","unstructured":"Guilhem A, Fargeton AE, Simon AC, et al.: Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): a retrospective study of 46 patients. PLoS One 2017; 12: e0188943.","DOI":"10.1371\/journal.pone.0188943"},{"key":"10.3238\/arztebl.m2024.0111_ref19","doi-asserted-by":"crossref","unstructured":"Chavan A, Luthe L, Gebel M, et al.: Complications and clinical outcome of hepatic artery embolisation in patients with hereditary haemorrhagic telangiectasia. Eur Radiol 2013; 23: 951–7.","DOI":"10.1007\/s00330-012-2694-9"},{"key":"10.3238\/arztebl.m2024.0111_ref20","doi-asserted-by":"crossref","unstructured":"Longacre AV, Gross CP, Gallitelli M, Henderson KJ, White RI Jr., Proctor DD: Diagnosis and management of gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol 2003; 98: 59–65.","DOI":"10.1111\/j.1572-0241.2003.07185.x"},{"key":"10.3238\/arztebl.m2024.0111_ref21","doi-asserted-by":"crossref","unstructured":"Dupuis-Girod S, Riviere S, Lavigne C, et al.: Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: a national, randomized multicenter trial. J Intern Med 2023; 294: 761–74.","DOI":"10.1111\/joim.13714"},{"key":"10.3238\/arztebl.m2024.0111_ref22","doi-asserted-by":"crossref","unstructured":"Geisthoff U, Nguyen HL, Lefering R, Maune S, Thangavelu K, Droege F: Trauma can induce telangiectases in hereditary hemorrhagic telangiectasia. J Clin Med 2020; 9: 1507.","DOI":"10.3390\/jcm9051507"},{"key":"10.3238\/arztebl.m2024.0111_ref23","doi-asserted-by":"crossref","unstructured":"Geisthoff UW, Fiorella ML, Fiorella R: Treatment of recurrent epistaxis in HHT. Curr Pharm Des 2006; 12: 1237–42.","DOI":"10.2174\/138161206776361255"},{"key":"10.3238\/arztebl.m2024.0111_ref24","doi-asserted-by":"crossref","unstructured":"Mei-Zahav M, Gendler Y, Bruckheimer E, et al.: Topical propranolol improves epistaxis control in hereditary hemorrhagic telangiectasia (HHT): a randomized double-blind placebo-controlled trial. J Clin Med 2020; 9: 3130.","DOI":"10.3390\/jcm9103130"},{"key":"10.3238\/arztebl.m2024.0111_ref25","doi-asserted-by":"crossref","unstructured":"Dupuis-Girod S, Fargeton AE, Grobost V, et al.: Efficacy and safety of a 0.1% tacrolimus nasal ointment as a treatment for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled, multicenter trial. J Clin Med 2020; 9: 1262.","DOI":"10.3390\/jcm9051262"},{"key":"10.3238\/arztebl.m2024.0111_ref26","doi-asserted-by":"crossref","unstructured":"Whitehead KJ, Sautter NB, McWilliams JP, et al.: Effect of topical intranasal therapy on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia: a randomized clinical trial. JAMA 2016; 316: 943–51.","DOI":"10.1001\/jama.2016.11724"},{"key":"10.3238\/arztebl.m2024.0111_ref27","doi-asserted-by":"crossref","unstructured":"Andorfer KEC, Zeman F, Koller M, et al.: TIMolol nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia (TIM-HHT)—a prospective, randomized, double-blind, controlled, cross-over trial. Pharmaceutics 2022; 14: 2335.","DOI":"10.3390\/pharmaceutics14112335"},{"key":"10.3238\/arztebl.m2024.0111_ref28","doi-asserted-by":"crossref","unstructured":"Bergler W, Sadick H, Gotte K, Riedel F, Hormann K: Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary hemorrhagic telangiectasia. Ann Otol Rhinol Laryngol 2002; 111: 222–8.","DOI":"10.1177\/000348940211100306"},{"key":"10.3238\/arztebl.m2024.0111_ref29","doi-asserted-by":"crossref","unstructured":"Wirsching KEC, Haubner F, Kuhnel TS: Influence of temporary nasal occlusion (tNO) on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia (HHT). Eur Arch Otorhinolaryngol 2017; 274: 1891–6.","DOI":"10.1007\/s00405-016-4431-5"},{"key":"10.3238\/arztebl.m2024.0111_ref30","doi-asserted-by":"crossref","unstructured":"Geisthoff UW, Heckmann K, D‘Amelio R, et al.: Health-related quality of life in hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg 2007; 136: 726–33.","DOI":"10.1016\/j.otohns.2006.12.019"},{"key":"10.3238\/arztebl.m2024.0111_ref31","doi-asserted-by":"crossref","unstructured":"Tunkel DE, Anne S, Payne SC, et al.: Clinical practice guideline: nosebleed (epistaxis). Otolaryngol Head Neck Surg 2020; 162:","DOI":"10.1177\/0194599819890327"},{"key":"10.3238\/arztebl.m2024.0111_ref32","unstructured":"S1–S38."},{"key":"10.3238\/arztebl.m2024.0111_ref33","doi-asserted-by":"crossref","unstructured":"Droege F, Lueb C, Thangavelu K, Stuck BA, Lang S, Geisthoff U: Nasal self-packing for epistaxis in hereditary hemorrhagic telangiectasia increases quality of life. Rhinology 2019; 57: 231–9.","DOI":"10.4193\/Rhin18.141"},{"key":"10.3238\/arztebl.m2024.0111_ref34","doi-asserted-by":"crossref","unstructured":"Gaillard S, Dupuis-Girod S, Boutitie F, et al.: Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost 2014; 12: 1494–502.","DOI":"10.1111\/jth.12654"},{"key":"10.3238\/arztebl.m2024.0111_ref35","doi-asserted-by":"crossref","unstructured":"Geisthoff UW, Seyfert UT, Kubler M, Bieg B, Plinkert PK, Konig J: Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid—a double-blind placebo-controlled cross-over phase IIIB study. Thromb Res 2014; 134: 565–71.","DOI":"10.1016\/j.thromres.2014.06.012"},{"key":"10.3238\/arztebl.m2024.0111_ref36","unstructured":"de Gussem EM, Snijder RJ, Disch FJ, Zanen P, Westermann CJ, Mager JJ: The effect of N-acetylcysteine on epistaxis and quality of life in patients with HHT: a pilot study. Rhinology 2009; 47: 85–8."},{"key":"10.3238\/arztebl.m2024.0111_ref37","doi-asserted-by":"crossref","unstructured":"Jorgensen G, Lange B, Wanscher JH, Kjeldsen AD: Efficiency of laser treatment in patients with hereditary hemorrhagic telangiectasia. Eur Arch Otorhinolaryngol 2011; 268: 1765–70.","DOI":"10.1007\/s00405-011-1677-9"},{"key":"10.3238\/arztebl.m2024.0111_ref38","doi-asserted-by":"crossref","unstructured":"Halderman AA, Ryan MW, Marple BF, Sindwani R, Reh DD, Poetker DM: Bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: an evidence-based review. Am J Rhinol Allergy 2018; 32: 258–68.","DOI":"10.1177\/1945892418768588"},{"key":"10.3238\/arztebl.m2024.0111_ref39","doi-asserted-by":"crossref","unstructured":"Stokes P, Rimmer J: Intranasal bevacizumab in the treatment of HHT-related epistaxis: a systematic review. Rhinology 2018; 56: 3–10.","DOI":"10.4193\/Rhin17.166"},{"key":"10.3238\/arztebl.m2024.0111_ref40","unstructured":"Uffenorde J, Georgi W: Einseitige Erblindung nach intranasaler Aethoxysklerol-Injektion. HNO 1983; 31: 236–8."},{"key":"10.3238\/arztebl.m2024.0111_ref41","doi-asserted-by":"crossref","unstructured":"Mabry RL: Intranasal corticosteroid injection: indications, technique, and complications. Otolaryngol Head Neck Surg (1979) 1979; 87: 207–11.","DOI":"10.1177\/019459987908700210"},{"key":"10.3238\/arztebl.m2024.0111_ref42","doi-asserted-by":"crossref","unstructured":"Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA: An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope 2010; 120: 838–43.","DOI":"10.1002\/lary.20818"},{"key":"10.3238\/arztebl.m2024.0111_ref43","doi-asserted-by":"crossref","unstructured":"Al-Samkari H, Kasthuri RS, Parambil JG, et al.: An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-bleed study. Haematologica 2021; 106: 2161–9.","DOI":"10.3324\/haematol.2020.261859"},{"key":"10.3238\/arztebl.m2024.0111_ref44","doi-asserted-by":"crossref","unstructured":"Buscarini E, Botella LM, Geisthoff U, et al.: Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis 2019; 14: 28.","DOI":"10.1186\/s13023-018-0982-4"},{"key":"10.3238\/arztebl.m2024.0111_ref45","unstructured":"Rosenberg T, Fialla AD, Kjeldsen J, Kjeldsen AD: Does severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series. Rhinology 2019; 57: 242–51."},{"key":"10.3238\/arztebl.m2024.0111_ref46","doi-asserted-by":"crossref","unstructured":"Hosman A, Westermann CJ, Snijder R, Disch F, Mummery CL, Mager JJ: Follow-up of thalidomide treatment in patients with hereditary haemorrhagic telangiectasia. Rhinology 2015; 53: 340–4.","DOI":"10.4193\/Rhin14.289"},{"key":"10.3238\/arztebl.m2024.0111_ref47","doi-asserted-by":"crossref","unstructured":"Al-Samkari H, Kasthuri RS, Iyer VN, et al.: PATH-HHT, a double-blind, randomized, placebo-controlled trial in hereditary hemorrhagic telangiectasia demonstrates that pomalidomide reduces epistaxis and improves quality of life. Blood 2023; 142 (Supplement 2): LBA-3.","DOI":"10.1182\/blood-2023-191983"},{"key":"10.3238\/arztebl.m2024.0111_ref48","doi-asserted-by":"crossref","unstructured":"Yaniv E, Preis M, Hadar T, Shvero J, Haddad M: Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Laryngoscope 2009; 119: 284–8.","DOI":"10.1002\/lary.20065"},{"key":"10.3238\/arztebl.m2024.0111_ref49","doi-asserted-by":"crossref","unstructured":"Fiorella ML, Ross D, Henderson KJ, White RI Jr.: Outcome of septal dermoplasty in patients with hereditary hemorrhagic telangiectasia. Laryngoscope 2005; 115: 301–5.","DOI":"10.1097\/01.mlg.0000154754.39797.43"},{"key":"10.3238\/arztebl.m2024.0111_ref50","doi-asserted-by":"crossref","unstructured":"Richer SL, Geisthoff UW, Livada N, et al.: The Young‘s procedure for severe epistaxis from hereditary hemorrhagic telangiectasia. Am J Rhinol Allergy 2012; 26: 401–4.","DOI":"10.2500\/ajra.2012.26.3809"},{"key":"10.3238\/arztebl.m2024.0111_ref51","doi-asserted-by":"crossref","unstructured":"Cubiro X, Garcia-Melendo C, Morales-Munera CE, et al.: Comparative treatment of mucocutaneous lesions in hereditary haemorrhagic telangiectasia patients with dual sequential pulsed dye laser and neodymium: yttrium-aluminium-garnet versus neodymium: yttrium-aluminium-garnet laser alone: a double-blind randomized controlled study with quality-of-life evaluation. Actas Dermosifiliogr 2024; 115: 246–57.","DOI":"10.1016\/j.ad.2023.10.017"},{"key":"10.3238\/arztebl.m2024.0111_ref52","doi-asserted-by":"crossref","unstructured":"Boyer H, Fernandes P, Le C, Yueh B: Prospective randomized trial of sclerotherapy vs standard treatment for epistaxis due to hereditary hemorrhagic telangiectasia. Int Forum Allergy Rhinol 2015; 5: 435–40.","DOI":"10.1002\/alr.21484"},{"key":"10.3238\/arztebl.m2024.0111_ref53","doi-asserted-by":"crossref","unstructured":"Dupuis-Girod S, Ambrun A, Decullier E, et al.: Effect of bevacizumab nasal spray on epistaxis duration in hereditary hemorrhagic telangectasia: a randomized clinical trial. JAMA 2016; 316: 934–42.","DOI":"10.1001\/jama.2016.11387"},{"key":"10.3238\/arztebl.m2024.0111_ref54","doi-asserted-by":"crossref","unstructured":"Dupuis-Girod S, Pitiot V, Bergerot C, et al.: Efficacy of TIMOLOL nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia. A double-blind, randomized, placebo-controlled trial. Sci Rep 2019; 9: 11986.","DOI":"10.1038\/s41598-019-48502-9"},{"key":"10.3238\/arztebl.m2024.0111_ref55","doi-asserted-by":"crossref","unstructured":"Khanwalkar AR, Rathor A, Read AK, Paknezhad H, Ma Y, Hwang PH: Randomized, controlled, double-blinded clinical trial of effect of bevacizumab injection in management of epistaxis in hereditary hemorrhagic telangiectasia patients undergoing surgical cauterization. Int Forum Allergy Rhinol 2022; 12: 1034–42.","DOI":"10.1002\/alr.22961"},{"key":"10.3238\/arztebl.m2024.0111_ref56","doi-asserted-by":"crossref","unstructured":"Luk L, Mace JC, Bhandarkar ND, Sautter NB: Comparison of electrosurgical plasma coagulation and potassium-titanyl-phosphate laser photocoagulation for treatment of hereditary hemorrhagic telangiectasia-related epistaxis. Int Forum Allergy Rhinol 2014; 4: 640–5.","DOI":"10.1002\/alr.21328"},{"key":"10.3238\/arztebl.m2024.0111_ref57","doi-asserted-by":"crossref","unstructured":"Peterson AM, Lee JJ, Kallogjeri D, Schneider JS, Chakinala MM, Piccirillo JF: Efficacy of timolol in a novel intranasal thermosensitive gel for hereditary hemorrhagic telangiectasia-associated epistaxis: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg 2020; 146: 1006–14.","DOI":"10.1001\/jamaoto.2020.3025"},{"key":"10.3238\/arztebl.m2024.0111_ref58","doi-asserted-by":"crossref","unstructured":"Pyne JM, Murray S, Kelly BC, Song JS, Rosvall BR, Cote DWJ: Surgiflo hemostatic matrix versus NasoPore nasal packing following postassium titanyl phosphate laser surgery for hereditary hemorrhagic telangiectasia: a randomized controlled trial. Laryngoscope Investig Otolaryngol 2023; 8: 328–34.","DOI":"10.1002\/lio2.1023"},{"key":"10.3238\/arztebl.m2024.0111_ref59","doi-asserted-by":"crossref","unstructured":"Riss D, Burian M, Wolf A, Kranebitter V, Kaider A, Arnoldner C: Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial. Head Neck 2015; 37: 783–7.","DOI":"10.1002\/hed.23655"},{"key":"10.3238\/arztebl.m2024.0111_ref60","doi-asserted-by":"crossref","unstructured":"Thompson KP, Sykes J, Chandakkar P, et al.: Randomized, double-blind, placebo-controlled, crossover trial of oral doxycycline for epistaxis in hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis 2022; 17: 405.","DOI":"10.1186\/s13023-022-02539-8"},{"key":"10.3238\/arztebl.m2024.0111_ref61","doi-asserted-by":"crossref","unstructured":"Vase P: Estrogen treatment of hereditary hemorrhagic telangiectasia. A double-blind controlled clinical trial. Acta Med Scand 1981; 209: 393–6.","DOI":"10.1111\/j.0954-6820.1981.tb11614.x"},{"key":"10.3238\/arztebl.m2024.0111_ref62","doi-asserted-by":"crossref","unstructured":"Kennedy SA, Faughnan ME, Vozoris NT, Prabhudesai V: Reperfusion of pulmonary arteriovenous malformations following embolotherapy: a randomized controlled trial of detachable versus pushable coils. Cardiovasc Intervent Radiol 2020; 43: 904–9.","DOI":"10.1007\/s00270-020-02422-8"},{"key":"10.3238\/arztebl.m2024.0111_ref63","doi-asserted-by":"crossref","unstructured":"Albinana V, Bernabeu-Herrero ME, Zarrabeitia R, Bernabeu C, Botella LM: Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): effects of raloxifene, on endoglin and ALK1 expression in endothelial cells. Thromb Haemost 2010; 103: 525–34.","DOI":"10.1160\/TH09-07-0425"},{"key":"10.3238\/arztebl.m2024.0111_ref64","doi-asserted-by":"crossref","unstructured":"Albinana V, Gimenez-Gallego G, Garcia-Mato A, et al.: Topically applied etamsylate: a new orphan drug for HHT-derived epistaxis (antiangiogenesis through FGF pathway inhibition). TH Open 2019; 3: e230–e43.","DOI":"10.1055\/s-0039-1693710"},{"key":"10.3238\/arztebl.m2024.0111_ref65","doi-asserted-by":"crossref","unstructured":"Contis A, Gensous N, Viallard JF, Goizet C, L\u00e9aut\u00e9-Labr\u00e8ze C, Duffau P: Efficacy and safety of propranolol for epistaxis in hereditary haemorrhagic telangiectasia: retrospective, then prospective study, in a total of 21 patients. Clin Otolaryngol 2016; 42: 911–7.","DOI":"10.1111\/coa.12821"},{"key":"10.3238\/arztebl.m2024.0111_ref66","unstructured":"Flanagan BA, Collins C, Parra S: Intranasal tranexamic acid for the treatment of hereditary hemorrhagic telangiectasia: a case report and review of treatment options. Cutis 2012; 89: 69–72."},{"key":"10.3238\/arztebl.m2024.0111_ref67","doi-asserted-by":"crossref","unstructured":"Klepfish A, Berrebi A, Schattner A: Intranasal tranexamic acid treatment for severe epistaxis in hereditary hemorrhagic telangiectasia. Arch Intern Med 2001; 161: 767.","DOI":"10.1001\/archinte.161.5.767"},{"key":"10.3238\/arztebl.m2024.0111_ref68","doi-asserted-by":"crossref","unstructured":"Kovacs-Sipos E, Holzmann D, Scherer T, Soyka MB: Nintedanib as a novel treatment option in hereditary haemorrhagic telangiectasia. BMJ Case Rep 2017; 2017: bcr2017219393.","DOI":"10.1136\/bcr-2017-219393"},{"key":"10.3238\/arztebl.m2024.0111_ref69","doi-asserted-by":"crossref","unstructured":"Kroon S, Snijder RJ, Hosman AE, et al.: Oral itraconazole for epistaxis in hereditary hemorrhagic telangiectasia: a proof of concept study. Angiogenesis 2021; 24: 379–86.","DOI":"10.1007\/s10456-020-09758-2"},{"key":"10.3238\/arztebl.m2024.0111_ref70","doi-asserted-by":"crossref","unstructured":"Reh DD, Hur K, Merlo CA: Efficacy of a topical sesame\/rose geranium oil compound in patients with hereditary hemorrhagic telangiectasia associated epistaxis. Laryngoscope 2013; 123: 820–2.","DOI":"10.1002\/lary.23736"},{"key":"10.3238\/arztebl.m2024.0111_ref71","doi-asserted-by":"crossref","unstructured":"Zarrabeitia R, Ojeda-Fernandez L, Recio L, et al.: Bazedoxifene, a new orphan drug for the treatment of bleeding in hereditary haemorrhagic telangiectasia. Thromb Haemost 2016; 115: 1167–77.","DOI":"10.1160\/TH15-03-0239"},{"key":"10.3238\/arztebl.m2024.0111_ref72","doi-asserted-by":"crossref","unstructured":"Hessels J, Kroon S, Boerman S, et al.: Efficacy and safety of tacrolimus as treatment for bleeding caused by hereditary hemorrhagic telangiectasia: an open-label, pilot study. J Clin Med 2022; 11: 5280.","DOI":"10.3390\/jcm11185280"},{"key":"10.3238\/arztebl.m2024.0111_ref73","doi-asserted-by":"crossref","unstructured":"Parambil JG, Gossage JR, McCrae KR, et al.: Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia. Angiogenesis 2022; 25: 87–97.","DOI":"10.1007\/s10456-021-09807-4"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2024.0111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T09:37:25Z","timestamp":1724837845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2024.0111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":73,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2024.0111","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]}}}